Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
To read the full story
Related Article
- PMDA Chief Fujiwara to Remain Skipper for Another Term
March 27, 2024
- Ex-PMDA Chief Kondo, Credited with Eliminating Japan’s Drug Lag, Dies at 79
September 30, 2021
- I’ve Done Everything I Can in 11 Years, Says Outgoing PMDA Chief
March 28, 2019
- National Cancer Center’s Fujiwara Named New PMDA Chief
March 27, 2019
- PMDA Chief Says Next Challenge Is to Boost Review Quality, Global Expansion Drive
January 9, 2018
- PMDA Stops Increasing Review Staff, Current Review-Time Targets to Remain Unchanged: Chief Executive
January 16, 2017
- Making PMDA World’s Most Trusted Regulatory Authority through “Regulatory Innovation”: Chief Executive
April 25, 2016
- PMDA Will Prosper by Promoting Review Work, Research, and Training Together: Chief Executive
August 13, 2014
- More Manpower, Knowledge Necessary for Giving New Drugs World’s First Approval: PMDA Chief Executive
January 17, 2014
- PMDA Eyes World’s First Approval for New Drugs: Chief Executive Kondo
August 28, 2012
- Interview with PMDA Chief Executive Tatsuya Kondo (2)
May 2, 2012
- Interview with PMDA Chief Executive Tatsuya Kondo (1)
May 1, 2012
- PMDA Should Support R&D from Patients' Viewpoints: New PMDA Chief Executive
April 21, 2008
REGULATORY
- Japan Ups Efforts to Better Communicate Pricing, Regulations to Overseas: Official
April 19, 2024
- MHLW Panel Sets Topics for PMD Act Amendment; Pediatrics, Drug Loss on Agenda
April 19, 2024
- Japan Govt Sued for Lack of Information on COVID Vaccine Risks
April 18, 2024
- MOF Ramps Up Push for Use of Cost-Effectiveness Assessment in Reimbursement Decisions
April 17, 2024
- PMDA Stepping Up Generic Compliance Inspections from August Approvals
April 16, 2024
On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…